Gilead's Twice-Yearly Shot Shows 100% Efficacy in Preventing HIV

Gilead's Twice-Yearly Shot Shows 100% Efficacy in Preventing HIV

Gilead Sciences Inc.'s experimental twice-yearly shot, lenacapavir, has shown 100% efficacy in preventing HIV infections in a Phase 3 trial involving over 5,300 women and adolescent girls aged 16 to 25 in South Africa and Uganda. The trial, which compared lenacapavir to older HIV prevention drugs, reported zero HIV infections among those who received the experimental shot. An independent data monitoring committee recommended that Gilead offer lenacapavir to all participants in the study, due to the promising results.

The success of lenacapavir, which is designed to be administered only twice a year, contrasts with other HIV prevention drugs that require more frequent dosing, such as daily pills or injections every two months. The drug, already approved under the brand name Sunlenca for treating resistant HIV infections, may soon be submitted for regulatory approval for preventive use in the U.S. and other countries. Following the trial's positive results, Gilead's shares rose by approximately 5.8% in New York trading. The company plans to share further data from additional studies later this year or early next year, with potential market entry as soon as 2025.

Summary

Other news in health